NXTC NextCure
Price Chart
Executive Summary
NextCure provided a business update and reported full-year 2025 financial results, highlighting anticipated clinical data readouts for its SIM0505 and LNCB74 ADC programs in 2026. The company expects to present Phase 1 dose escalation data for SIM0505 in Q2 2026 and initiate a dose optimization study in ovarian cancer, while continuing enrollment in the LNCB74 trial. Cash resources of $41.8 million are expected to fund operations into early 2027.
Key Financial Metrics
Actionable Insight
Monitor upcoming clinical data readouts in 2026 as key catalysts; watch cash runway and potential need for future financing if development timelines extend.
Key Facts
- Phase 1 dose escalation data for SIM0505 expected in Q2 2026
- Dose optimization study for SIM0505 in platinum-resistant ovarian cancer to begin in Q2 2026
- LNCB74 Phase 1 trial update planned for second half of 2026
- Cash, cash equivalents, and marketable securities were $41.8 million as of December 31, 2025
- Net loss was $55.8 million for full year 2025, flat vs. $55.7 million in 2024
- Research and development expenses increased to $44.9 million from $41.5 million in 2024
- General and administrative expenses decreased to $12.7 million from $15.7 million in 2024
- Current cash expected to fund operations into first half of 2027
Financial Impact
Cash burn of $26.8 million in 2025; R&D up $3.4 million due to $18.5M in SIM0505 license fees; G&A down $3.0M
Risk Factors
- Clinical trial results may not meet expectations, particularly given early-phase stage
- Cash runway extends only to mid-2027; future equity financing could lead to dilution
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250665 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 7, 2026
13d ago
|
8-K
| $9.76 $10.25 | ▲ +5.02% | ▲ +3.56% | $9.86 (+1.02%) |
|
May 4, 2026
17d ago
|
Press Release
| $8.92 $9.78 | ▲ +9.64% | ▲ +6.71% | $9.86 (+10.54%) |
|
Apr 24, 2026
26d ago
|
DEFA14A
| $9.62 $8.92 | ▼ −7.28% | ▼ −7.68% | $9.86 (+2.49%) |
|
Apr 21, 2026
4w ago
|
Press Release
| $10.97 $9.25 | ▼ −15.68% | ▼ −16.76% | $9.86 (−10.12%) |
|
Mar 5, 2026
10w ago
|
8-K
| $12.39 $12.68 | ▲ +2.34% | ▲ +3.87% | $9.86 (−20.42%) |
|
Mar 5, 2026
10w ago
|
Press Release
| $12.39 $12.68 | ▲ +2.34% | ▲ +3.87% | $9.86 (−20.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access